Rabbit myocardial lysophospholipase was purified 27,000-fold to near homogeneity by ammonium sulfate precipitation, DEAE-Sephacel, gel filtration, chromatofocusing, and hydroxylapatite chromatography. Chromatofocusing demonstrated two activity peaks, each with a molecular mass of 23,000 daltons by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Both activity peaks had similar kinetic parameters (Vmax = 7 mumols/mg/min, Km = 9-11 microM) and similar pH profiles (7.5 optimum). Each activity peak was competitively inhibited by L-palmitoylcarnitine with similar inhibitory constants (KI = 10-11 microM). In addition, palmitic acid competitively inhibited myocardial lysophospholipase (KI = 37 microM). A rapid loss of lysophospholipase activity resulted from heating at 37 degrees C in the absence of substrate (t1/2 = 3 min). This thermal denaturation was attenuated similarly by either lysophosphatidylcholine (15 microM) or L-palmitoylcarnitine (15 microM). Thus, L-palmitoylcarnitine complexes with purified myocardial lysophospholipase and competitively inhibits a major pathway of lysophosphatidylcholine catabolism, thereby potentially contributing to accumulation of lysophosphatides in ischemic myocardium and ventricular dysrhythmia.
No takes yet. Share an insight, caveat, or question.
Gross et al. (1983) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: